| Patient | Audre Lorde |
|---|---|
| Date of birth | 1981-02-18 |
| Identifiers | MRN HR-ML016-SYN; SSN (made up) 000-16-2937 |
| Document date | 2026-11-01 |
| Author | Naomi Fairweather, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care survivorship visit five and a half months after right mastectomy for stage IA breast cancer, on tamoxifen. Concerns: Moving her breast cancer survivorship care to primary care, with the oncology team kept informed; mild hot flashes on tamoxifen; Wants complete information and to make her own decisions. She chose a flat closure without reconstruction and does not wish to wear an external prosthesis; she asks that this not be raised again unless she raises it. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five years | One tablet once daily | Oral route | 2025-10-27 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Diagnostic bilateral mammography after a self-detected right breast lump: 1.6 cm irregular mass in the upper outer right breast, BI-RADS 5; left breast normal | 2025-09-08 to 2025-09-08 | completed | S |
| Right breast and axillary ultrasound: 1.6 cm irregular hypoechoic mass at 10 o'clock; normal axillary lymph nodes | 2025-09-08 to 2025-09-08 | completed | S |
| Ultrasound-guided core needle biopsy of the right breast mass: invasive ductal carcinoma, grade 2; ER 90 percent, PR 60 percent, HER2 1+ (negative), Ki-67 12 percent | 2025-09-10 to 2025-09-10 | completed | S |
| Right total mastectomy with flat closure and no reconstruction, her informed choice. Pathology: invasive ductal carcinoma 1.6 cm, grade 2, margins clear, no lymphovascular invasion; pT1c pN0(sn), stage IA. Recurrence score (21-gene assay) 14 | 2025-09-26 to 2025-09-26 | completed | S |
| Right axillary sentinel lymph node biopsy at mastectomy: 0 of 2 nodes involved | 2025-09-26 to 2025-09-26 | completed | S |
| Diagnostic mammography of the left breast one year after diagnosis: scattered fibroglandular tissue, no suspicious findings, BI-RADS 1 | 2026-09-21 to 2026-09-21 | completed | S |
| Genetic counseling for hereditary breast cancer risk: pedigree taken and multigene panel testing for inherited cancer risk sent; result pending at the end of the episode | 2026-10-05 to 2026-10-05 | completed | S |
| Cervical sampling for cytology with human papillomavirus co-testing; result pending at the end of the episode | 2026-10-19 to 2026-10-19 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-14 | Influenza vaccine, 2025-2026 season | completed | S |
| 2019-05-06 | Tdap vaccine | completed | S |
| 2026-10-19 | Influenza vaccine, 2026-2027 season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1977 | Breast tumor found by a doctor, benign after about three weeks of uncertainty | D (CLM-0003) |
| 1978 | Lump in the right breast found at self-examination on Labor Day, followed by a diagnosis of breast cancer and a mastectomy; she declined a breast prosthesis | D (CLM-0004, CLM-0005) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Moving her breast cancer survivorship care to primary care, with the oncology team kept informed; mild hot flashes on tamoxifen | active | S |
| Wants complete information and to make her own decisions. She chose a flat closure without reconstruction and does not wish to wear an external prosthesis; she asks that this not be raised again unless she raises it | active | S |
Most recent measures: Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-06-29; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 2 on 2026-06-29; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-19; Cholesterol [Mass/volume] in Serum or Plasma 182 on 2026-10-19; Cholesterol in HDL [Mass/volume] in Serum or Plasma 64 on 2026-10-19; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 98 on 2026-10-19; Triglyceride [Mass/volume] in Serum or Plasma 100 on 2026-10-19; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 2026-10-19; Total score [AUDIT-C] 1 on 2026-10-19 [S]
Strengths and supports: Supports: her family and a wide circle of writers and friends [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1978 breast cancer and mastectomy | active | confirmed | C50.411 | S — Synthetic tumor details and treatment; the diagnosis and the mastectomy are documented (D), but no tumor details from her lifetime are used. |
| Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no receptor status from her lifetime is known. |
| Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesis | active | confirmed | Z90.11 | S — Synthetic coding of the documented mastectomy; the decision about a prosthesis echoes her documented choice and is respected as her own. |
| Long-term use of tamoxifen as adjuvant endocrine therapy | active | confirmed | Z79.810 | S — Synthetic treatment status. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-03-09 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S | ||
| 2026-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-06-29 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 2 | {score} | S | ||
| 2026-09-28 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-19 | Cholesterol [Mass/volume] in Serum or Plasma | 182 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-10-19 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 64 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-10-19 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 98 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-10-19 | Triglyceride [Mass/volume] in Serum or Plasma | 100 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-19 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | <=5.6% | Normal | S |
| 2026-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-19 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-09 | Body height | 168 | cm | S |
| 2026-03-09 | Body weight | 72 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 25.5 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 74 | /min | S |
| 2026-03-09 | Respiratory rate | 14 | /min | S |
| 2026-03-09 | Body temperature | 36.7 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-03-30 | Body height | 168 | cm | S |
| 2026-03-30 | Body weight | 72.4 | kg | S |
| 2026-03-30 | Body mass index (BMI) [Ratio] | 25.7 | kg/m2 | S |
| 2026-03-30 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-03-30 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-30 | Heart rate | 72 | /min | S |
| 2026-03-30 | Respiratory rate | 14 | /min | S |
| 2026-03-30 | Body temperature | 36.6 | Cel | S |
| 2026-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-06-29 | Body height | 168 | cm | S |
| 2026-06-29 | Body weight | 71.6 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 25.4 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 70 | /min | S |
| 2026-06-29 | Respiratory rate | 14 | /min | S |
| 2026-06-29 | Body temperature | 36.7 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-09-28 | Body height | 168 | cm | S |
| 2026-09-28 | Body weight | 71.8 | kg | S |
| 2026-09-28 | Body mass index (BMI) [Ratio] | 25.4 | kg/m2 | S |
| 2026-09-28 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-09-28 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-28 | Heart rate | 72 | /min | S |
| 2026-09-28 | Respiratory rate | 14 | /min | S |
| 2026-09-28 | Body temperature | 36.6 | Cel | S |
| 2026-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-19 | Body height | 168 | cm | S |
| 2026-10-19 | Body weight | 71.5 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 25.3 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 70 | /min | S |
| 2026-10-19 | Respiratory rate | 14 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-09 | Primary care survivorship visit five and a half months after right mastectomy for stage IA breast cancer, on tamoxifen | finished | S |
| 2026-03-30 | Survivorship follow-up on the day of the medical oncology consultation | finished | S |
| 2026-06-29 | Three-month survivorship visit on tamoxifen | finished | S |
| 2026-09-28 | Survivorship visit one year after diagnosis, after the yearly mammogram of the left breast | finished | S |
| 2026-10-19 | Adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Medical oncology consultation to confirm the adjuvant endocrine therapy plan, advise on hot flashes, set the surveillance plan, and advise on genetic assessment | completed | GL-NCCN-BREAST-2025, GL-ASCO-ENDO-2019 | S |
| Tamoxifen 20 mg daily for at least five years, with questions at every visit about hot flashes, abnormal vaginal bleeding, and leg swelling or breathlessness, and a yearly gynecologic assessment | completed | GL-ASCO-ENDO-2019, GL-CMID-2026 | S |
| Cancer-related history and examination every 3 to 6 months for the first 3 years and a yearly diagnostic mammogram of the left breast; no routine blood tests, tumor markers, or body imaging while she has no symptoms | completed | GL-CMID-2026, GL-ACS-ASCO-SURV-2016, GL-ASCO-FU-2013 | S |
| Germline genetic counseling and multigene panel testing for breast cancer diagnosed at 44 | completed | GL-ASCO-SSO-GERM-2024, GL-NCCN-BREAST-2025 | S |
| Lymphedema risk counseling and arm checks at every visit; bone health by calcium and vitamin D from diet and weight-bearing exercise; distress, depression, and anxiety screening at intervals | completed | GL-ACS-ASCO-SURV-2016, GL-CMID-2026 | S |
| Written survivorship care plan, at least 150 minutes of activity a week, alcohol at or below one drink a day, and her decisions about reconstruction and a prosthesis recorded and respected | completed | GL-ACS-ASCO-SURV-2016, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Continue tamoxifen daily with side effects she finds tolerable | 2026-09-28 | completed | Taking it daily; mild hot flashes controlled without medicine; no abnormal bleeding or clot symptoms | S |
| Complete the yearly surveillance mammogram of the left breast | 2026-09-28 | completed | Left mammogram one year after diagnosis: BI-RADS 1 | S |
| Complete germline genetic assessment, missed at diagnosis | 2026-10-19 | active | Genetic counseling completed and panel testing sent; result pending | S |
| Keep at least 150 minutes of activity a week and a stable weight | 2026-09-28 | completed | Walking about 200 minutes a week; weight stable at 71 to 72 kg | S |